About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...
TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...
"PICASSO will revolutionize photonic circuit architectures, from compute to light detection and ranging, by expanding the field’s focus from individual components to include a more holistic circuit- ...
Introducing multiple Arm64 variants of the JIT_WriteBarrier function. Each variant is tuned for a GC mode. Because many parts ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...
It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...
Social media has long been a valuable source of personally identifiable information (PII) for cybercriminals, but the rise of ...
CNW/ - ("Fireweed" or the "Company") (TSXV: FWZ) (OTCQX: FWEDF) is pleased to report the initial results of a major step-out ...
Texas A&M AgriLife faculty, staff and graduate students earn Vice Chancellor’s Awards in Excellence honors at Texas A&M ...
Implementing predictive analytics can become one of the biggest competitive differentiators for any educational institution ...
New Space is a term now commonly used around the rocketry and satellite industries to indicate a new, speed focused model of ...
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback